Connect with us

Most Active Stocks Today? 5 Defensive Stocks For Your Watchlist

Are defensive stocks the right move amid soaring inflation?
The post Most Active Stocks Today? 5 Defensive Stocks For Your Watchlist appeared first on…

Published

on

5 Defensive Stocks To Watch In the Stock Market This Week

As we enter a new trading week, investors could be on the lookout for defensive stocks in the stock market. For one, this would be due to the Consumer Price Index (CPI), which rose 8.6% year-over-year in May. This came as a surprise as it exceeded the 8.3% Wall Street was estimating. In addition to that, consumer sentiment slumped to a record low between May and June amid concerns about inflation. As such, investors could be turning to defensive stocks. These are companies from sectors such as healthcare and consumer staples, which tend to see more stable demand in any economic condition.

An example of a defensive stock that investors could be watching this week is Kroger (NYSE: KR). The consumer staple company is set to report its financials from the most recent quarter before the market opens on Thursday. As it stands, Wall Street is expecting the company to report earnings of $1.27 per share on revenues of $44 billion for the quarter, representing year-over-year increases of 6.7% and 6.5% respectively. With that in mind, check out these defensive stocks in the stock market today.

Defensive Stocks To Watch Right Now

Procter & Gamble 

Starting us off today is Procter & Gamble (PG). Put simply, the company focuses on providing branded consumer packaged goods to consumers across the world. PG operates through five segments: Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. Under these segments are brands such as Head & Shoulders, Herbal Essences, SK-II, Oral-B, Downy, and many more. Last Wednesday, the company and Microsoft (NASDAQ: MSFT) announced a new multi-year collaboration.

Namely, the consumer staple company is looking to leverage the Microsoft Cloud to help create the future of digital manufacturing at PG. “Together with Microsoft, P&G intends to make manufacturing smarter by enabling scalable predictive quality, predictive maintenance, controlled release, touchless operations and manufacturing sustainability optimization — which has not been done at this scale in the manufacturing space to date,” said PG’s CIO Vittorio Cretella. With Microsoft Azure as the foundation, the new collaboration marks the first time PG will digitize and integrate its data from more than 100 manufacturing sites around the world. Thus, will you be buying PG stock?

Proctor Gamble Stock
Source: TD Ameritrade TOS

[Read More] Stock Market Today: Dow Jones, S&P 500 Continue To Slide; Coinbase Stock Plunges Amid Sharp Pullback In Bitcoin Price

Ollie’s Bargain Outlet 

Following that, we have Ollie’s Bargain Outlet. As the name suggests, the company operates a chain of discount retail stores. Ollie’s offers a wide array of brand-name products ranging from housewares, daily essentials, and even toys. Notably, the company operates over 400 locations across 28 states, catering to discount shoppers. Last week, the company posted results for the first quarter of the year, with net sales tumbling 10% to $406.7 million. 

The company said this was due to last year’s inflated results from the third round of stimulus checks consumers received. However, thanks to the company’s bullish outlook, OLLI stock rose by over 10% last week. According to the earnings report, the company is forecasting sales to be in the range of $450 million to $460 million for the second quarter. Along with that, it expects adjusted earnings for the same period to be between $0.32 and $0.35 per share. Given this positive outlook, will you be keeping tabs on OLLI stock?

OLLI stock chart
Source: TD Ameritrade TOS

Campbell Soup Company 

Next, we have Campbell Soup, a company that has been around for generations. Although most would know it for its canned soup products, Campbell has actually grown to become one of the world’s largest processed food companies in the U.S. The company products can be split into two distinct divisions, Meals & Beverages and Snacks, with 13 core categories. Its brands include the likes of Prego, Campbell’s, and Pepperidge Farm to name a few. 

Last Wednesday, the company reported its third-quarter financials for fiscal 2022. Diving in, net sales for the quarter increased 7% year-over-year to $2.1 billion. This comes as demand for Campbell’s products remains strong, with consumption also increasing by 4% year-over-year. Along with that, it reported net earnings per share of $0.62, jumping by 15% compared to a year earlier. In the same earnings report, Campbell also said that it is raising its full-year fiscal 2022 sales outlook and reaffirming its prior adjusted EBIT and adjusted EPS guidance. All things considered, is CPB stock worth investing in right now?

CPB stock chart
Source: TD Ameritrade TOS

[Read More] Cheap Stocks To Buy Now? 3 Cyclical Stocks In Focus

Target Corporation 

General merchandise retailer Target sells products through its retail stores and digital channels. Its product category includes apparel and accessories, beauty and household essentials, food and beverage, hardlines, and home furnishing and decor. Last Thursday, the board of directors declared a quarterly dividend of $1.08 per common share, a 20% increase from $0.90 in the quarter prior. This also marks its 220th consecutive dividend paid since October 1967.

Besides that, Target also announced its updated plan for the year. The company is planning several actions to right-size its inventory for the remainder of the year. Target says this is to create “flexibility in serving guests in a rapidly changing environment.” As part of its strategy, Target will be adding incremental holding capacity close to U.S. ports, taking pricing actions, and removing excess inventory. Moreover, it also aims to work with suppliers to improve lead times in the supply chain. Seeing that TGT stock has been down more than 30% in the past month, should you consider buying the dip?

Target stock
Source: TD Ameritrade TOS

Eli Lilly and Company 

Last but not least, we have Eli Lilly and Company (LLY). It is a health care company that primarily engages in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. In brief, the company’s portfolio includes treatments for various diseases including diabetes, cancer, endocrine-related illnesses, and Covid-19, to name a few. 

Earlier this month, LLY and Boehringer Ingelheim announced that their Jardiance (empagliflozin) drug was associated with a reduction in risk of hospitalization for heart failure in adults with Type 2 diabetes. According to Mohamed Eid, Boehringer Ingelheim’s head of clinical development and medical affairs, the findings suggest that empagliflozin has a well-understood safety and tolerability profile as well. As it stands, LLY and Boehringer Ingelheim have been working hard to establish their competitive footprint in the diabetes and cardiovascular treatment landscapes. Given this, should you add LLY stock to your watchlist?

LLY stock chart
Source: TD Ameritrade TOS

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Most Active Stocks Today? 5 Defensive Stocks For Your Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

International

Repeated COVID-19 Vaccination Weakens Immune System: Study

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19…

Published

on

Repeated COVID-19 Vaccination Weakens Immune System: Study

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Repeated COVID-19 vaccination weakens the immune system, potentially making people susceptible to life-threatening conditions such as cancer, according to a new study.

A man is given a COVID-19 vaccine in Chelsea, Mass., on Feb. 16, 2021. (Joseph Prezioso/AFP via Getty Images)

Multiple doses of the Pfizer or Moderna COVID-19 vaccines lead to higher levels of antibodies called IgG4, which can provide a protective effect. But a growing body of evidence indicates that the “abnormally high levels” of the immunoglobulin subclass actually make the immune system more susceptible to the COVID-19 spike protein in the vaccines, researchers said in the paper.

They pointed to experiments performed on mice that found multiple boosters on top of the initial COVID-19 vaccination “significantly decreased” protection against both the Delta and Omicron virus variants and testing that found a spike in IgG4 levels after repeat Pfizer vaccination, suggesting immune exhaustion.

Studies have detected higher levels of IgG4 in people who died with COVID-19 when compared to those who recovered and linked the levels with another known determinant of COVID-19-related mortality, the researchers also noted.

A review of the literature also showed that vaccines against HIV, malaria, and pertussis also induce the production of IgG4.

“In sum, COVID-19 epidemiological studies cited in our work plus the failure of HIV, Malaria, and Pertussis vaccines constitute irrefutable evidence demonstrating that an increase in IgG4 levels impairs immune responses,” Alberto Rubio Casillas, a researcher with the biology laboratory at the University of Guadalajara in Mexico and one of the authors of the new paper, told The Epoch Times via email.

The paper was published by the journal Vaccines in May.

Pfizer and Moderna officials didn’t respond to requests for comment.

Both companies utilize messenger RNA (mRNA) technology in their vaccines.

Dr. Robert Malone, who helped invent the technology, said the paper illustrates why he’s been warning about the negative effects of repeated vaccination.

“I warned that more jabs can result in what’s called high zone tolerance, of which the switch to IgG4 is one of the mechanisms. And now we have data that clearly demonstrate that’s occurring in the case of this as well as some other vaccines,” Malone, who wasn’t involved with the study, told The Epoch Times.

So it’s basically validating that this rush to administer and re-administer without having solid data to back those decisions was highly counterproductive and appears to have resulted in a cohort of people that are actually more susceptible to the disease.”

Possible Problems

The weakened immune systems brought about by repeated vaccination could lead to serious problems, including cancer, the researchers said.

Read more here...

Tyler Durden Sat, 06/03/2023 - 22:30

Read More

Continue Reading

Spread & Containment

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Twitter…

Published

on

Robert F. Kennedy Jr. Banned By Major Social Media Site, Campaign Pages Blocked

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Twitter owner Elon Musk invited Democrat presidential candidate Robert F. Kennedy Jr. for a discussion on his Twitter Spaces after Kennedy said his campaign was suspended by Meta-owned Instagram.

Interesting… when we use our TeamKennedy email address to set up @instagram accounts we get an automatic 180-day ban. Can anyone guess why that’s happening?” he wrote on Twitter.

An accompanying image shows that Instagram said it “suspended” his “Team Kennedy” account and that there “are 180 days remaining to disagree” with the company’s decision.

Robert F. Kennedy, Jr. attends Keep it Clean to benefit Waterkeeper Alliance in Los Angeles, Calif., on March 1, 2018. (John Sciulli/Getty Images for Waterkeeper Alliance)

In response to his post, Musk wrote: “Would you like to do a Spaces discussion with me next week?” Kennedy agreed, saying he would do it Monday at 2 p.m. ET.

Hours later, Kennedy wrote that Instagram “still hasn’t reinstated my account, which was banned years ago with more than 900k followers.” He argued that “to silence a major political candidate is profoundly undemocratic.”

“Social media is the modern equivalent of the town square,” the candidate, who is the nephew of former President John F. Kennedy, wrote. “How can democracy function if only some candidates have access to it?”

The Epoch Times approached Instagram for comment.

It’s not the first time that either Facebook or Instagram has taken action against Kennedy. In 2021, Instagram banned him from posting claims about vaccine safety and COVID-19.

After he was banned by the platform, Kennedy said that his Instagram posts raised legitimate concerns about vaccines and were backed by research. His account was banned just days after Facebook and Instagram announced they would block the spread of what they described as misinformation about vaccines, including research saying the shots cause autism, are dangerous, or are ineffective.

“This kind of censorship is counterproductive if our objective is a safe and effective vaccine supply,” he said at the time.

Read more here...

Tyler Durden Sat, 06/03/2023 - 20:30

Read More

Continue Reading

International

Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch…

Published

on

Study Falsely Linking Hydroxychloroquine To Increased Deaths Frequently Cited Even After Retraction

Authored by Jessie Zhang via Thje Epoch Times (emphasis ours),

An Australian and Swedish investigation has found that among the hundreds of COVID-19 research papers that have been withdrawn, a retracted study linking the drug hydroxychloroquine to increased mortality was the most cited paper.

Hydroxychloroquine sulphate tablets. (Memories Over Mocha/Shutterstock)

With 1,360 citations at the time of data extraction, researchers in the field were still referring to the paper “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis” long after it was retracted.

Authors of the analysis involving the University of Wollongong, Linköping University, and Western Sydney Local Health District wrote (pdf) that “most researchers who cite retracted research do not identify that the paper is retracted, even when submitting long after the paper has been withdrawn.”

“This has serious implications for the reliability of published research and the academic literature, which need to be addressed,” they said.

Retraction is the final safeguard against academic error and misconduct, and thus a cornerstone of the entire process of knowledge generation.”

Scientists Question Findings

Over 100 medical professionals wrote an open letter, raising ten major issues with the paper.

These included the fact that there was “no ethics review” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.”

A bottle of Hydroxychloroquine at the Medicine Shoppe in Wilkes-Barre, Pa on March 31, 2020. Some politicians and doctors were sparring over whether to use hydroxychloroquine against the new coronavirus, with many scientists saying the evidence is too thin to recommend it yet. (Mark Moran/The Citizens’ Voice via AP)

Other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts, which would present skewed results.

They also found that the data that was reportedly from Australian patients did not seem to match data from the Australian government.

Eventually, the study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK.

France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials.

Currently, a total of 337 research papers on COVID-19 have been retracted, according to Retraction Watch.

Further retractions are expected as the investigation of proceeds.

Tyler Durden Sat, 06/03/2023 - 17:30

Read More

Continue Reading

Trending